Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of advances in the design and manufacture of rt-CGM systems, providing those with Type 1 diabetes with access to technology and the ability to self-monitor their glucose levels to avoid hyper- and hypoglycaemia in a less intrusive way to monitoring through blood tests.

Treatments may be brought into routine use in the National Health Service after their efficacy, safety, and cost-effectiveness have been appropriately demonstrated. The National Institute for Health and Care Excellence (NICE) is responsible for assessing new technologies and interventional procedures, as well as producing guidelines for best practice of treatment and care.

NICE has produced diagnostics guidance on technologies for managing blood glucose levels in people with type 1 diabetes. These integrated sensor-augmented pump therapy systems combine continuous glucose monitoring with continuous subcutaneous insulin infusion.